Kisspeptin

Summary

Kisspeptin (encoded by the KISS1 gene) is an endogenous neuropeptide family that acts as a master regulator of the HPG axis. Its synthetic analogs (e.g., kisspeptin-10, kisspeptin-54) are under clinical investigation for conditions including hypogonadotropic hypogonadism, infertility, polycystic ovary syndrome, and as a trigger for oocyte maturation in IVF. It also has emerging roles in metabolic regulation and sexual behavior.

Mechanism of Action

Kisspeptin binds to the KISS1R (GPR54) receptor on hypothalamic GnRH neurons, stimulating pulsatile release of gonadotropin-releasing hormone (GnRH), which in turn drives pituitary secretion of LH and FSH, thereby activating the hypothalamic-pituitary-gonadal (HPG) axis.

Routes of Administration

Goals & Uses

• Tumor metastasis suppression (anti-metastatic)OncologyLow
• Diagnosis of GnRH deficiency (functional test)Diagnostic EndocrinologyModerate
• Treatment of hypogonadotropic hypogonadismEndocrinologyModerate
• Improvement of sexual arousal / libidoSexual MedicineLow
• Restoration of reproductive function in hypothalamic amenorrheaReproductive MedicineModerate
• Induction of ovulation / oocyte maturation trigger in IVFReproductive MedicineModerate

Contraindications

• Hormone-sensitive malignanciesOncologyHigh
• Known hypersensitivity to kisspeptin or excipientsAllergy/ImmunologyHigh
• Pituitary insufficiencyEndocrinologyModerate
• Pregnancy (outside of controlled IVF protocols)ObstetricsModerate

Adverse Effects

• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Hot flushesVasomotorUncommon
• Ovarian hyperstimulation syndrome (OHSS)ReproductiveRare

Drug Interactions

• GnRH agonists / antagonists (e.g., leuprolide, cetrorelix)Moderate
• Exogenous gonadotropins (FSH, LH, hCG)Moderate
• OpioidsLow

Population Constraints

• Pediatric populations (prepubertal)AgeRelative
• Patients with active endometriosisGynecologicalRelative
• BreastfeedingReproductiveRelative
• Renal or hepatic impairmentOrgan DysfunctionRelative

Regulatory Status

• European UnionInvestigationalNo EMA marketing authorization; subject of multiple academic and industry-sponsored trials.
• United StatesInvestigationalNo FDA approval; studied under IND in clinical trials for infertility and hypogonadism.
• United KingdomInvestigationalExtensive clinical research conducted at Imperial College London under MHRA oversight; no approved product as of 2024.

No jurisdiction has granted full marketing approval for any kisspeptin therapeutic as of 2024. Used as an investigational agent in clinical trials; kisspeptin-54 has been studied in Phase I/II trials in the UK (Imperial College London) and elsewhere for reproductive indications.

Evidence & Sources

No sources recorded yet.